AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36075200
Drug: Hemadsorption therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemadsorption therapy (HT) using a CytoSorb® adsorber for up to 5 days, replaced every 18-24 hours.
Trial: 36075200
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (SMT).
Trial: 36075200
Drug: Hemadsorption therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemadsorption therapy (HT)
Trial: 32147046
Drug: Mulberry leaves
RxNorm normalized name: digitalis leaves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mulberry leaves (12 mg of mulberry DNJ three times daily)
Trial: 32147046
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0 mg of DNJ)
Trial: 35797235
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) AZD7442, 600 mg
Trial: 35797235
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) AZD7442, 300 mg
Trial: 34984028
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D 5000 IU once daily plus standard treatment (pregabalin, gabapentin, or amitriptyline) for 8 weeks
Trial: 33289129
Drug: C‐dots at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C‐dots at a concentration of 530 g L‐1
Trial: 35126684
Drug: SHR4640 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR4640 10 mg plus febuxostat 80 mg
Trial: 35126684
Drug: SHR4640 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR4640 10 mg plus febuxostat 40 mg
Trial: 35126684
Drug: SHR4640 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR4640 5 mg plus febuxostat 20 mg
Trial: 34554694
Drug: Pulsed Radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Radiofrequency (PRF) treatment of the saphenous nerve
Trial: 34554694
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (sham procedure with motor stimulation)
Trial: 32121066
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of Undaria pinnatifida fucoidan (UPF)
Trial: 35720066
Drug: Safinamide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safinamide (50 mg/day for 2 weeks and 100 mg/day for 22 weeks)
Trial: 36367004
Drug: Nalbuphine 10
RxNorm normalized name: nalbuphine 10 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 10 mg and sufentanil (NS1)
Trial: 36367004
Drug: Nalbuphine 10
RxNorm normalized name: nalbuphine 10 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 10 mg and sufentanil 20 mg (NS2)
Trial: 36367004
Drug: Nalbuphine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 30 mg and sufentanil 20 mg (NS3)
Trial: 33471169
Drug: Intranasal sodium
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal sodium citrate
Trial: 32694705
Drug: Non-pharmaceutical dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmaceutical dry eye therapy
Trial: 32694705
Drug: Daily saline
RxNorm normalized name: SODIUM CHLORIDE 0.9 g in 100 mL NASAL AEROSOL, SPRAY [EQUATE DAILY SALINE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily saline eye wash
Trial: 33930408
Drug: Teprotumumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teprotumumab (8 infusions every 3 weeks)
Trial: 32002650
Drug: 4-aminopyridine for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-aminopyridine for the symptomatic treatment of episodic ataxia type 2 and downbeat nystagmus
Trial: 615413969
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus thrice-weekly progressive aerobic exercise (S+PAE)
Trial: 615413969
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus thrice-weekly non-progressive exercise (S+NPE)
Trial: 34941317
Drug: Shared decision-making
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shared decision-making (SDM) for treatment planning (n = 20)
Trial: 34941317
Drug: Clinician-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-guided treatment planning (n = 20)
Trial: 33484027
Drug: Ivabradine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine plus conventional treatment (IG)
Trial: 33484027
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment alone (CG)
Trial: 33385766
Drug: Grape seed
RxNorm normalized name: grape seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape seed extract (GSE) 100 mg/day
Trial: 33238677
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (0.6 ml/kg)
Trial: 32017660
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (treatment program consisting of only modalities, range of motion [ROM], and strength training but no PSSEs)
Trial: 33068819
Drug: Negative control
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative control with no treatment
Trial: 33469832
Drug: Tolterodine 4
RxNorm normalized name: tolterodine 4 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 4 mg extended release
Trial: 32009091
Drug: Lenalidomide plus
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide plus dexamethasone (15 mg in cycle 1, 25 mg in cycles 2-6, dexamethasone 20 mg once a week)
Trial: 33453514
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (ET) 3 times/week for 12 weeks
Trial: 34335819
Drug: Garlic tablets
DrugBank: Garlic (DB10532)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic tablets (400 mg)
Trial: 34768722
Drug: Novel influenza
RxNorm normalized name: Novel influenza-H1N1-09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel influenza vaccine with continuous monitoring using a wearable sensor.
Trial: 33535811
Drug: Experimental COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental COVID-19 vaccine
Trial: 33535811
Drug: Active comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator vaccine
Trial: 34210242
Drug: Co-supplementation group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-supplementation group (n = 27): 50000 IU vitamin D soft gel weekly + 250 mg magnesium tablet daily
Trial: 34210242
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D group (n = 27): 50000 IU vitamin D soft gel weekly + magnesium placebo daily
Trial: 34210242
Drug: Magnesium group
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium group (n = 27): vitamin D placebo weekly + 250 mg magnesium tablet daily
Trial: 34210242
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 27): vitamin D placebo weekly + magnesium placebo daily
Trial: 37949090
Drug: Moxidectin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxidectin (8 mg)
Trial: 33657442
Drug: Alcoholic drink
RxNorm normalized name: Alcoholic drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcoholic drink (0.6 g/kg)
Trial: 33657442
Drug: Alcoholic drink
RxNorm normalized name: Alcoholic drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcoholic drink (0.3 g/kg)
Trial: 33130217
Drug: pm‐Pac (230
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pm‐Pac (230 mg/m2) plus cisplatin (70 mg/m2)
Trial: 33130217
Drug: sb‐Pac (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sb‐Pac (175 mg/m2) plus cisplatin (70 mg/m2)
Trial: 32318809
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg daily for 7 days
Trial: 34678981
Drug: Sevelamer (2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevelamer (2400 mg daily)
Trial: 34678981
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (1500 mg daily)
Trial: 32821251
Drug: Recollection-based occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recollection-based occupational therapy program (24 sessions, 5 times per week for 1 hour each)
Trial: 34131002
Drug: Prexasertib at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prexasertib at 70 mg/m2 i.v. with olaparib at 100 mg by mouth twice daily
Trial: 32763538
Drug: Repetitive transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive transcranial magnetic stimulation (rTMS), 20 treatments over four weeks
Trial: 36459264
Drug: CHARISMA intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHARISMA intervention to increase women's agency to use oral pre‐exposure prophylaxis (PrEP) safely and consistently.
Trial: 33892086
Drug: Effective Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effective Dose 50 (ED50) method for depression
Trial: 35609409
Drug: Standard pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pemetrexed maintenance therapy
Trial: 34006055
Drug: 3% Hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% Hypertonic saline (HS) solution
Trial: 35334570
Drug: L-alanyl L-glutamine
RxNorm normalized name: L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-alanyl L-glutamine dipeptide
Trial: 33831213
Drug: Exenatide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (2 mg, subcutaneously, once-weekly)
Trial: 33831213
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT, 21 mg)
Trial: 34867725
Drug: Passive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive treatment (historical control)
Trial: 34867725
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (historical control)
Trial: 34867725
Drug: Prism Adaptation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prism Adaptation treatment with fewer therapy sessions (historical control)
Trial: 34758057
Drug: High flow:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flow: 70 l · min‐1, continuous jaw thrust
Trial: 34758057
Drug: Medium flow:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium flow: 10 l · min‐1, continuous jaw thrust
Trial: 34758057
Drug: Low flow:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low flow: 2 l · min‐1, continuous jaw thrust
Trial: 34758057
Drug: Minimal flow:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal flow: 0.25 l · min‐1, endotracheal tube
Trial: 34362525
Drug: Non ABO‐HDN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non ABO‐HDN direct antibody test
Trial: 33932000
Drug: Fluoxetine hydrochloride
RxNorm normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine hydrochloride capsule 20 mg once a day
Trial: 35603590
Drug: Fibre/water (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre/water (2 l/day)
Trial: 33616613
Drug: Telephone Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone Cognitive Behavioral Therapy for Insomnia (CBT-I)
Trial: 32876697
Drug: Fixed-dose hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed-dose hydrocortisone (50 mg or 100 mg every 6 hours)
Trial: 32876697
Drug: Shock-dependent hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Shock-dependent hydrocortisone (50 mg every 6 hours when shock was clinically evident)
Trial: 36009980
Drug: Colistin combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin combined with sulbactam at 12 g/day
Trial: 36009980
Drug: Colistin combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin combined with sulbactam at 9 g/day
Trial: 32617651
Drug: Subchondral cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subchondral cell therapy (20 mL of bone marrow concentrate with 5727 MSCs/mL)
Trial: 32617651
Drug: Intra-articular cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular cell therapy (20 mL of bone marrow concentrate with 5727 MSCs/mL)
Trial: 32202692
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered in the same dosing schedule as oxytocin)
Trial: 35631293
Drug: CBD (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (30 mg)
Trial: 35631293
Drug: CBD (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (30 mg) with food
Trial: 33931829
Drug: Peloid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peloid therapy + home exercise program
Trial: 35000098
Drug: Single-dose paltusotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose paltusotine 1.25 to 20 mg
Trial: 35000098
Drug: Multiple-dose paltusotine
RxNorm normalized name: Paltusotine
DrugBank: Paltusotine (DB16277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose paltusotine 5 to 30 mg administered once daily for 10 days
Trial: 34189636
Drug: Trabectedin 1.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin 1.1 mg/m2 plus pegylated liposomal doxorubicin (PLD) 30 mg/m2, administered intravenously every 21 days until disease progression or unacceptable toxicity.
Trial: 32212418
Drug: Oral moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral moxifloxacin 400 mg (positive control)
Trial: 35289500
Drug: Olmesartan medoxomil/amlodipine
RxNorm normalized name: olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide 40 mg-5 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil/amlodipine besylate tablet (20 mg/5 mg) under fasting conditions
Trial: 35289500
Drug: Olmesartan medoxomil/amlodipine
RxNorm normalized name: olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide 40 mg-5 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil/amlodipine besylate tablet (20 mg/5 mg) under fed conditions
Trial: 32165403
Drug: FENO guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FENO guided treatment (not treated with LTRA)
Trial: 32165403
Drug: FENO guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FENO guided treatment (non-obese children)
Trial: 35652746
Drug: Centanafadine 200
RxNorm normalized name: Centanafadine
DrugBank: Centanafadine (DB14841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centanafadine 200 mg/d
Trial: 35652746
Drug: Centanafadine 400
RxNorm normalized name: Centanafadine
DrugBank: Centanafadine (DB14841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centanafadine 400 mg/d
Trial: 36272502
Drug: DON group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DON group (10 mg DON/kg of feed)
Trial: 32762663
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-Acetylcysteine (NAC) at a fixed dose of 2.7 g/day (900 mg three times daily) for 12 weeks
Trial: 36321334
Drug: VSD combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VSD combined with flap transplantation and immunosuppressive agent treatment
Trial: 36321334
Drug: Normal dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal dressing change combined with hormone and cyclosporine
Trial: 33763794
Drug: Pilocarpine administration
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine administration
Trial: 33039671
Drug: Initial care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial care for early fasting hyperglycaemia (n = 137, FPG ≥ 5.5 mmol/L)
Trial: 33992615
Drug: Lipiflow treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipiflow treatment 3 weeks before cataract surgery
Trial: 33992615
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Lipiflow treatment)
Trial: 36110574
Drug: Anti-PD-1 immunotherapy
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 immunotherapy (sintilimab) combined with gemcitabine chemotherapy
Trial: 34147766
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus Enhanced Medication Management (SERT + EMM)
Trial: 34147766
Drug: Prolonged Exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged Exposure plus Sertraline (PE + SERT)
Trial: 35610575
Drug: Water (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (5 mL/kg)
Trial: 35610575
Drug: High-carbohydrate drink
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-carbohydrate drink (5 mL/kg)
Trial: 36048382
Drug: Aqueous extract
RxNorm normalized name: green tea aqueous extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous extract of seed of broccoli, dosage and duration not available
Trial: 33140122
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of inorganic nitrate (NO3−); specific dosage and duration not mentioned.
Trial: 35932386
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A (fed condition)
Trial: 35932386
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A (multiple doses)
Trial: 33113440
Drug: Dietary alpha-lipoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary alpha-lipoic acid (ALA) supplementation (300 mg/kg)
Trial: 37858247
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) supplementation
Trial: 35244070
Drug: Nerve block
RxNorm normalized name: Nerve Block Tray 22g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve block therapy (NBT) + acupotomy
Trial: 35244070
Drug: Nerve block
RxNorm normalized name: Nerve Block Tray 22g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve block therapy (NBT)
Trial: 33778937
Drug: Intraperitoneal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal glucose injection
Trial: 33778937
Drug: Glutamate antagonist
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate antagonist (CNQX + refeeding)
Trial: 33778937
Drug: Glutamate antagonist
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate antagonist (CNQX + glucose)
Trial: 33789971
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT) - two sessions
Trial: 34392573
Drug: Hydrogen peroxide
RxNorm normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrogen peroxide topical solution 35% (H2 O2)
Trial: 35549757
Drug: Qingpeng ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingpeng ointment applied topically at involved joints twice a day for consecutive 7 days
Trial: 35549757
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment applied topically at involved joints twice a day for consecutive 7 days
Trial: 32098501
Drug: Exenatide 2
RxNorm normalized name: exenatide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 2 mg
Trial: 32098501
Drug: Any glucose-lowering
RxNorm normalized name: biguanide blood glucose lower drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any glucose-lowering medication
Trial: 32098501
Drug: All glucose-lowering
RxNorm normalized name: biguanide blood glucose lower drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All glucose-lowering medications
Trial: 32098501
Drug: Cardioprotective glucose-lowering
RxNorm normalized name: biguanide blood glucose lower drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioprotective glucose-lowering agents